Innoen Applies for Phase 1 Clinical Trial of COVID-19 Vaccine
[Asia Economy Reporter Chunhee Lee] On the 30th, Inno.N announced that it has submitted a clinical phase 1 trial plan for the recombinant protein COVID-19 vaccine candidate 'IN-B009' under development to the Ministry of Food and Drug Safety. Through phase 1 clinical trials, Inno.N plans to focus on evaluating safety and immunogenicity in healthy adults.
The COVID-19 vaccine candidate IN-B009 developed by Inno.N is a recombinant protein vaccine manufactured by producing viral antigen proteins using genetic recombination technology. The antigen protein is a substance that induces immune activity against the spike protein of the COVID-19 virus, characterized by enhancing the production rate of 'neutralizing antibodies' that neutralize viral activity and cellular immune activation.
Among currently developed vaccines, it is similar to the Novavax vaccine. SK Bioscience and UbioLogics are also developing vaccines of the same type.
Last year, Inno.N received the COVID-19 vaccine candidate technology from the Korea Research Institute of Chemical Technology's Emerging Virus Fusion Research Group (CEVI) and has been conducting efficacy and non-clinical studies together with the Virus Prevention Team of the Fusion Research Group.
Currently, IN-B009 has confirmed effective neutralizing antibody formation rates and safety in non-clinical trials on primates. Additionally, in the vaccine test group where immune cell activation was induced after administration, no proliferation of the COVID-19 virus occurred, and efficacy was shown against various variant viruses found in the UK and South Africa.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- After Losing Her Only Daughter, a Mother in China Gave Birth to Twins at 60... Reinventing Life at 76
- [PollPollNews] President Lee’s Approval Rating at 60.5%... Rises for Second Consecutive Week, Returns to 60% Range
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Jeong Eunju, head of Inno.N's Biotechnology Center, said, "We will strive to develop the product quickly to escape the long-lasting risk of COVID-19 infection." Based on the safety and efficacy results secured in non-clinical trials, Inno.N plans to commence phase 1 clinical trials as soon as the clinical trial plan is approved.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
